In this article
FDA Approval of Tafasitamab-cxix for Follicular Lymphoma
On June 18, 2025, the Food and Drug Administration sanctioned tafasitamab-cxix (Monjuvi, Incyte Corporation) in conjunction with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL).
Safety and Efficacy
The efficacy was assessed in inMIND, a double-blind, placebo-controlled trial (NCT04680052) that randomized 548 patients with relapsed or refractory follicular lymphoma to receive tafasitamab-cxix or placebo in conjunction with lenalidomide and rituximab. Patients had undergone a median of 1 previous line of systemic therapy; 25% and 20% had received 2 and 3 or more prior lines, respectively.
The primary effectiveness outcome measure was investigator-evaluated progression-free survival (PFS). Following a median follow-up of 14.1 months, progression-free survival (PFS) was statistically substantially prolonged in the tafasitamab-cxix group (hazard ratio 0.43 [95% CI: 0.32, 0.58]; p-value <0.0001). The projected median progression-free survival (PFS) was 22.4 months (95% CI: 19.2, not evaluable) for the tafasitamab-cxix group and 13.9 months (95% CI: 11.5, 16.4) for the control group.
Severe adverse events were observed in 33% of patients in the tafasitamab-cxix group, with serious infections affecting 24%. The prescribing information for tafasitamab-cxix contains warnings and precautions about infusion-related reactions, myelosuppression, and infections.
Suggested Dosage
The advised dosage of tafasitamab-cxix is 12 mg/kg administered as an intravenous infusion for a maximum of 12 cycles in conjunction with lenalidomide and rituximab. Tafasitamab-cxix is not advised or recommended for patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.